Keiji Miyazawa is scheduled to assume office as Representative Director, President, and Chief Operating Officer (COO) on June 23, 2026. He holds 4,407 shares.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-04-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4547-20260424-01.pdf","jir_short_summary":"Keiji Miyazawa is scheduled to assume office as Representative Director, President, and Chief Operating Officer (COO) on June 23, 2026. He holds 4,407 shares.","jir_summary":"### Overview of Change in Representative Director\nKissei Pharmaceutical Co., Ltd. resolved at the Board of Directors meeting on April 24, 2026, to appoint a new Representative Director. Keiji Miyazawa is scheduled to assume the position of Representative Director, President, and Chief Operating Officer (COO) as part of strengthening the management structure to realize the Mid-Term Management Plan Beyond 80. The formal decision will be made at the Ordinary General Meeting of Shareholders and Board of Directors meeting on June 23, 2026.\n\n### Profile and Shareholding Status of the New Representative Director\nKeiji Miyazawa was born on April 14, 1967, and joined the company in April 1993. Since then, he has held key positions in the Research Division and has served as Director of the Research Division and KISSEI AMERICA, INC. since June 2022. He currently holds 4,407 shares. The scheduled appointment date is June 23, 2026.","jir_financial_highlights":"Number of Shares Held: 4,407 shares (Unknown)\nScheduled Appointment Date: 2026-06-23 (Unknown)","jir_category":"","jir_hashtags":"#KisseiPharmaceutical, #ExecutivePersonnelChange, #JapaneseStocks","jir_key_figures":"Scheduled Appointment Date: 2026-06-23\nNew Representative Director, President and COO: Keiji Miyazawa\nNumber of Shares Held: 4,407 shares","jir_meta_title":"Kissei Pharmaceutical: Keiji Miyazawa Scheduled to Become New President | June 2026","jir_meta_description":"Kissei Pharmaceutical announced that Keiji Miyazawa is scheduled to assume office as Representative Director, President, and Chief Operating Officer on June 23, 2026. This change aims to strengthen the management structure to realize the Mid-Term Management Plan Beyond 80.","jir_og_title":"Kissei Pharmaceutical: Keiji Miyazawa Scheduled as New President | June 2026","jir_og_description":"Kissei Pharmaceutical plans for Keiji Miyazawa to assume the role of Representative Director and President on June 23, 2026, aiming to reinforce its management structure.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-42519","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n